Index

Note: Page references followed by ‘f’ refer to Figures; those followed by ‘t’ refer to Tables

18F-fluorodeoxyglucosePET (18FDG-PET) 124, 172–3, 171f
in AD 175, 177f, 179f, 453
in epilepsy 173, 174f
6-OHDA 52

Abbey Pain Scale 637t, 638
acalculia 306t
accelerometer data 206, 208
accelerometers 208, 212
accommodation 296, 297f

Accountable Care Organizations (ACO) 716

Acquired alexia 305
Active ageing, WHO definition 19
Activities of daily living (ADL) 28, 673, 674
Activities-Specific Balance Confidence Scale 328
Activity management 640t
Acunar strokes 491
Acute disseminated encephalomyelitis (ADEM) 570
Acute dystonic reaction 535
Acute stress disorder (ASD) 209
Acute vestibular syndrome 327
Additional singleton paradigm 349, 349f
Administrative policy targeting persons with dementia 711
Basic research 711
Programs and services 711–12
Adult day care services 677
Aerobic exercise 367
Affordable Care Act (ACA) 711

Age Discrimination in Employment Act of 1967 (ADEA) 743, 752, 753, 754, 755
Ageism 80, 742–56
Altered mental status 553
Altman, Robert 91
Alprostadil (Muse) in erectile dysfunction 400, 401
All Together Now project 93
Alzheimer’s disease (AD) 103, 120t, 175–83, 177f, 179f, 180t, 181f, 181t, 183f, 264–5, 447–8, 449–56, 494, 531, 582, 599
Aging brain model (ABM) 424
Aging of Mind and Brain (AMB) 26–9
Aging, definition of 38
Agitation in AD 471
Agnosia 305
Akinesia 524
Alcohol consumption, stroke and 488
Alcohol withdrawal 578
Alexia 306t
with agraphia 306t
without agraphia 306t
Acquired 305
Aging-related macular degeneration (AMD) 298, 299f, 301, 302, 304, 308
Alzheimer’s disease (AD) (cont’d)
amyloid-beta (Aβ) plaques in 63, 179–83, 455, 460
animal models of major genetic mutations in 63
Cerebral amyloid angiopathy 575
clinical diagnosis 449–50, 450t
CSF biomarkers 454–5
diagnostic criteria 471–3, 472t
DNA strand breakage 41
education and 64
EEG 124
epidemiology 449
exercise in 655–6
gait impairment in 317
general neurologic examination 451
genetic testing 125, 454
incidence 25
laboratory tests 451
lumbar puncture 454
mitochondrial genomic dysfunction 43
neurofibrillary tangles (NFTs) 63, 455, 456
neuroimaging 451–3
neuropsychological testing 453
pathophysiology 455–6
PET Imaging 175–83, 176–7f
amyloid imaging 179–82, 180t, 181t, 181f
appropriate use criteria 182–3f
glucose metabolism in 177–8f
role of imaging in dementia 175
tau imaging 183
phases of progression 764–5
psychotic symptoms 546, 547
rodent models of 69
simulation in primates 70
sleep in 619
tau-protein in 63, 455, 456, 460–1
see also Alzheimer’s disease, treatments
Alzheimer’s disease, treatments 462–71
disease modifying 464–5
FDA-approved drugs 462t
noncognitive symptoms 468–71, 468t
agitation 471
apathy 471
assessment 469
behavioral management 469
depression 469, 545
frequency of behavioral changes 468t
frequency of symptoms 468–9
pharmacologic treatments 469, 470t
psychosis 469
symptomatic 462
under investigation 465–8
amyloid treatments 466–8
anti-inflammatory medications 465
estrogen replacement therapy 465–6
Alzheimer’s Disease and Related Dementias Research Act of 1986 709
Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) 463
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 175, 452, 711
Alzheimerization of aging 95
amaurosis fugax 486
American Brain Coalition 765
American Time Use Survey 207f
Americans with Disabilities Act (ADA) 752
amnestic mild cognitive impairment 458
amnestic syndrome 572
Amour (film) 92
AMP-activated protein kinase (AMPK) 48
amphetamines 492
amyloid imaging 179–83, 180f, 453
amyloid precursor protein (APP) 456, 456f
amyloid spills 575
amyloid treatments 466–8
amyloid-beta (Aβ) plaques in 63, 455, 460
amyloid-beta-40 124
amyloid-beta-42 124
amyloid-β related angiitis (ABRA) 575
amyotrophic lateral sclerosis (ALS) 264
anal endosonography 405
anorexias 494
Angelou, Maya 82
anger 419
angle closure glaucoma 298
angular VOR (AVOR) 324
anhedonia 106
animal models of pathological aging 61–71
anorexia nervosa 560
anosia 112, 116
anosodiaphoria 104
anosognosia 104
antagonistic pleiotropy 39
antecollis 535
anterior cerebral artery (ACA) 484
anterior inferior cerebellar artery (AICA) 328
antibiotic-associated encephalopathy 580–1
anticholinergic agents
side effects of 107
in urge incontinence 394
anti-contactin-associated protein-2 (Caspr2) antibody encephalitis 569
anti-NMDA receptor antibody encephalitis 568
anti-VGKC-complex antibody encephalitis 568–9, 569f
Anton’s syndrome 573
anxiety disorders 547–9
apathy in AD 471
aphasias 116
expressive 116
APOE gene 125, 575
apomorphine in erectile dysfunction 400
APoEs, role of 604
APP gene 125
apparent diffusion coefficient (ADC) 151, 152
Apple Health 216
Apple Watch 216, 220
aprosody 527
Aristotle 82
Aronson, Louise: History of the Present Illness, A 83
arterial dissection 492
arterial spin labeling (ASL) perfusion MRI 141, 156
arteriovenous malformation (AVM) 494, 495f
arts as age studies 80
aging and 80–2
and sciences collaborations between 81
aging mind and 78–97
arts therapies 81
aseptic (lymphocytic) meningitis 562
Ashkenazi Jewish centenarians 53
Assessment of Older Adults with Diminished Capacity: A Handbook for Psychologists 727, 728
astereognosis 110
asterixis 538, 556
ataxia 111
ataxia-telangiectasia (A-T) 40
ataxic gait 111
atrial fibrillation, stroke and 488
attention and processing speed 337–56
electrophysiology of spatial attention 340–1
laboratory measurements 338–46
electrophysiology and visual search 343
electrophysiology of spatial attention 340–1
eye movements 343–5
spatial cueing 338, 339f
spatial mechanisms 338–40
useful field of view (UFOV) 340, 343, 345–6
models of aging and attention 352–6
dorsolateral prefrontal cortex and context integration 355–56
frontal lobe function 354–5
goal-driven modulation 356
inhibition 354
processing speed 352–4
attention deficit disorder 131
attentional capture 348, 349–51
auditory hallucinations 106, 547
auditory system 328–31
anatomy of 328–9
dysfunction of 330–1
physiology of 329–30
authentic pride 421
Autobiographical Memory Questionnaire (AMQ) 136
autobiography 84
autoimmune diseases 573
autoimmune limbic encephalitis 565
autonomy diminished 691–2
improving awareness to optimize 693(box)
respect for, and diminished cognitive capacity 693
and self-determination 690–1
autoscopy 326
autosomal dominant polycystic kidney disease 488, 494
Away From Her (film) 83, 92
AX-CPT 355
axial diffusivity (AD) 152
Babinski sign 110
BACE inhibitors 466
bacterial meningitis, acute 561–2
balance 115, 315–16
balance and gait disorders (BGDs) 316
balance/gait system 316
changes with age 317–18
physiology of 316–17
Bálint syndrome 138, 305, 306f, 484, 571, 573
Ballad of Narayama, The (film) 91
ballism 538
balloon expulsion test 405
Banks v. Goodfellow 725
bapineuzumab 467
Barnes, Julian: “Appetite” 83
Barthel Index (BI) 507, 509
base excision repair (BER) enzymes 41
basic fitness trackers 216
Basting, Anne: TimeSlips creative storytelling project 85
Bayley, John: Elegy for Iris 84
Beauty of Age Documentary Project 92
Beauvoir, Simone de 82
Beck Depression Inventory 139
BEHAVE-AD 469
behaviors 22
Behçet disease 562
Bell’s palsy 114
### Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research</strong></td>
<td>726</td>
</tr>
<tr>
<td>benign paroxysmal positional vertigo (BPPV)</td>
<td>327, 328</td>
</tr>
<tr>
<td>Benton Visual Memory Test (BVMT)</td>
<td>136</td>
</tr>
<tr>
<td>Benton’s Facial Recognition Test (FRT)</td>
<td>138</td>
</tr>
<tr>
<td>Bergman, Ingmar</td>
<td>91</td>
</tr>
<tr>
<td>beta-amyloid (Aβ)</td>
<td>453</td>
</tr>
<tr>
<td>biballism</td>
<td>538</td>
</tr>
<tr>
<td>Binswanger’s disease</td>
<td>510</td>
</tr>
<tr>
<td>biofeedback therapy</td>
<td>394, 406–7</td>
</tr>
<tr>
<td>bipolar disorder</td>
<td>543–5</td>
</tr>
<tr>
<td>black box event recorder sensors</td>
<td>215f</td>
</tr>
<tr>
<td>bladder control</td>
<td>107</td>
</tr>
<tr>
<td>bladder retraining</td>
<td>394</td>
</tr>
<tr>
<td>bladder training</td>
<td>394</td>
</tr>
<tr>
<td>blast-induced neurotrauma (BINT)</td>
<td>592, 596, 597</td>
</tr>
<tr>
<td>Blessed Dementia Scale (BDS), Orientation-Memory-Concentration part of 554</td>
<td></td>
</tr>
<tr>
<td>Blessed Orientation-Memory-Concentration Test</td>
<td>450</td>
</tr>
<tr>
<td>blind-sight</td>
<td>306t</td>
</tr>
<tr>
<td>blood oxygen level dependency (BOLD)</td>
<td>124, 154, 189, 356</td>
</tr>
<tr>
<td>blood oxygen saturation</td>
<td>213</td>
</tr>
<tr>
<td>Bloom’s syndrome</td>
<td>40</td>
</tr>
<tr>
<td>blue coma</td>
<td>579</td>
</tr>
<tr>
<td>body mass index (BMI)</td>
<td>108</td>
</tr>
<tr>
<td>bona fide occupational qualification (BFOQ)</td>
<td>753</td>
</tr>
<tr>
<td>borderline personality disorder</td>
<td>549</td>
</tr>
<tr>
<td>Boston Diagnostic Aphasia Examination</td>
<td>132, 137</td>
</tr>
<tr>
<td>Boston Famous Faces Test</td>
<td>136</td>
</tr>
<tr>
<td>Boston Naming Test</td>
<td>138</td>
</tr>
<tr>
<td>Complex Ideational Test</td>
<td>137</td>
</tr>
<tr>
<td>Boston school of neuropsychological assessment (process approach)</td>
<td>132</td>
</tr>
<tr>
<td>Bourgeois, Louise</td>
<td>87</td>
</tr>
<tr>
<td>Braak hypothesis</td>
<td>528</td>
</tr>
<tr>
<td>brachial diplegia</td>
<td>571</td>
</tr>
<tr>
<td>bradykinesia</td>
<td>524, 526</td>
</tr>
<tr>
<td>brain, aging and 37–53, 39f and organinal aging 52–3</td>
<td></td>
</tr>
<tr>
<td>vs. pathological changes in motor system</td>
<td>525t</td>
</tr>
<tr>
<td>brain abscess</td>
<td>562</td>
</tr>
<tr>
<td>brain infections</td>
<td>390</td>
</tr>
<tr>
<td>brain size and gender</td>
<td>390</td>
</tr>
<tr>
<td>brain-computer interface (BCI)</td>
<td>698, 699</td>
</tr>
<tr>
<td>brain-derived neurotrophic factor (BDNF)</td>
<td>47, 64</td>
</tr>
<tr>
<td>brainstem</td>
<td>112, 113f</td>
</tr>
<tr>
<td>Brief Visual Memory Test-Revised (BVMT-R)</td>
<td>136</td>
</tr>
<tr>
<td>Brinley plots</td>
<td>352</td>
</tr>
<tr>
<td>Broadbent, Jim</td>
<td>91, 92</td>
</tr>
<tr>
<td>Broca’s aphasia</td>
<td>116, 484</td>
</tr>
<tr>
<td>Broca’s area</td>
<td>279</td>
</tr>
<tr>
<td>Broken Chord, The (stage production)</td>
<td>81f</td>
</tr>
<tr>
<td>Brownian motion</td>
<td>151</td>
</tr>
<tr>
<td>Brudzinski’s sign</td>
<td>554</td>
</tr>
<tr>
<td>burst-tonic (BT) neurons</td>
<td>324</td>
</tr>
<tr>
<td>Burton, Robert A.: <em>A Skeptic’s Guide to the Mind</em></td>
<td>95</td>
</tr>
<tr>
<td>Butler, Robert</td>
<td>82, 85</td>
</tr>
<tr>
<td>CADASIL (cerebral autosomal recessive arteriopathy with subcortical infarct and leucoencephalopathy)</td>
<td>488, 512</td>
</tr>
<tr>
<td>Caenorhabditis elegans</td>
<td>40, 64–6</td>
</tr>
<tr>
<td>“dauer” stage</td>
<td>65</td>
</tr>
<tr>
<td>decreased IIS signaling</td>
<td>49</td>
</tr>
<tr>
<td>klotho gene</td>
<td>61</td>
</tr>
<tr>
<td>model of aging</td>
<td>47, 48</td>
</tr>
<tr>
<td>model of pathological aging</td>
<td></td>
</tr>
<tr>
<td>advantages and disadvantages of 62t</td>
<td></td>
</tr>
<tr>
<td>ROS in 63</td>
<td>65</td>
</tr>
<tr>
<td>α-synuclein</td>
<td>65</td>
</tr>
<tr>
<td>calibrated finger rub auditory screening test</td>
<td>115</td>
</tr>
<tr>
<td>California Verbal Learning Test (CVLT)</td>
<td>135, 136</td>
</tr>
<tr>
<td>caloric restriction (CR)</td>
<td>48</td>
</tr>
<tr>
<td>Cambridge Neuropsychological Test Automated Battery (CANTAB)</td>
<td>256</td>
</tr>
<tr>
<td>Campo, Rafael: “The Mental Status Room”</td>
<td>83–4</td>
</tr>
<tr>
<td>capacity</td>
<td>692</td>
</tr>
<tr>
<td>assessment of 727–35</td>
<td></td>
</tr>
<tr>
<td>vs. competency</td>
<td>725–6</td>
</tr>
<tr>
<td>to consent to research</td>
<td>730f</td>
</tr>
<tr>
<td>diminished 726–7</td>
<td></td>
</tr>
<tr>
<td>examination 733–5</td>
<td></td>
</tr>
<tr>
<td>for independent living</td>
<td>730f</td>
</tr>
<tr>
<td>to make medical treatment decision: 730f</td>
<td></td>
</tr>
<tr>
<td>recommendations 736–7</td>
<td></td>
</tr>
<tr>
<td>capacity, model for evaluation of 728–32</td>
<td></td>
</tr>
<tr>
<td>clinical judgment of capacity</td>
<td>732</td>
</tr>
<tr>
<td>cognitive underpinnings</td>
<td>729–30</td>
</tr>
<tr>
<td>competency and capacity in the aging adult</td>
<td>729–31</td>
</tr>
<tr>
<td>diagnosis 729</td>
<td></td>
</tr>
<tr>
<td>enhancing capacity</td>
<td>732</td>
</tr>
<tr>
<td>functional elements</td>
<td>729–30</td>
</tr>
<tr>
<td>legal standards</td>
<td>728–9, 730f</td>
</tr>
<tr>
<td>psychiatric/emotional factors</td>
<td>731</td>
</tr>
</tbody>
</table>
Index 773

risk 731–2
values 731
Capgras Syndrome 106
carbon monoxide poisoning 576–7, 577f
cardiorespiratory fitness (CRF) 652t
care services, long-term 673–82
abuse, harm, or neglect 705
community and 673–82
community-based 676–7
family 675–6
future of 682
residential 677–81
caregiver education 640t
Carrey, Jim 219
cataract 298, 302
cavernous hemangioma 494, 496f
   cellular mechanisms that drive aging 40–50
   altered intercellular signaling 47–8
   cellular senescence 45–6
   genomic instability 40–1
   metabolism and nutrient signaling 48–50
   mitochondrial damage 42–4
   protein damage 44–5
telomere attrition 41–2
Center for Digital Storytelling (CDS) 93
central nervous system (CNS) infections 103
central vestibulopathies 327
cerebellar ataxia 570
cerebral achromatopsia 306t
cerebral akinetopsia 305, 306t
cerebral amyloid angiopathy (CAA) 492, 494–5, 495f, 514
   CAA-related inflammation 512
   cerebral amyloid angiopathy (CAA)-related inflammation (CAA-RI) 575
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 488, 512
cerebral diplopia or polyopia 306t
cerebral septic thrombophlebitis 562
cerebral venous/sinus thrombosis 487
cerebrovascular disease 103, 483–509
   acute management 495–500
   emergency treatment of acute hemorrhagic stroke 498–500
   emergency treatment of acute ischemic stroke 497–8
   general emergency management 495–7
   cerebral blood flow imaging 167–71
cerebrovascular reserve 171, 171f
   clinical presentations 484–7
   cerebral venous/sinus thrombosis 487
   common stroke syndromes 484
   hemorrhagic stroke 487
   ischemic stroke 484
   transient ischemic attack (TIA) 485–7
   clinicometrics 507–9
   community knowledge and stroke education 509
   complications of stroke 503–4
   epidemiology 483–4
   evaluation of patients with stroke 500–3, 501f, 502f
   mechanism of 488–95
   hemorrhagic stroke 492–5
   ischemic stroke 488–92
   recovery and rehabilitation 507
   risk factors 488
   modifiable risk 488
nonmodifiable risks 488
   secondary stroke prevention 504–7, 504t
   Certified Nursing Assistant Pain Assessment Tool (CPAT) 637t
cervical dystonia 535
CHA2DS2 and CHADS2 and VASc score guides 506
Charcot, Jean-Martin 117
Charcot-Bouchard microaneurysms 492
Charles Bonnet syndrome 106, 307t, 484, 547
Checklist of Nonverbal Pain Indicators [CNPI] 637, 637t
chemical meningitis 562
chemotherapy-induced encephalopathy 580
chorea 536–7, 556
choreoathetosis 556
Christie, Agatha 82
Christie, Julie 92
chronic obstructive pulmonary disease (COPD) 560
chronic traumatic encephalopathy (CTE) 591, 592–3
Churg-Strauss syndrome 512
Chvostek’s sign 557
Cicero 82
cinematherapy 92–3
Civil Rights Act of 1964 743, 752, 755
Civil Rights Amendment of 1991 755
Clinical Dementia Rating scale (CDR) 450
Clinician’s Interview-Based Impression of Change plus carer interview (CIBIC Plus) 463
clouding of consciousness 554
CMV 562, 563
cocaine 492
cochlear implants 331
Index

cock-walk 532

cog wheeling 526

cognitive changes, medical
evaluation of 122f

cognitive complaints, common
vs abnormal 105t

Cognitive Complexity and
Control (CC) theory 256

cognitive control hypothesis
(CCH) 424–5

cognitive decline, practical
indices of 107

cognitive empathy 421

cognitive enhancement 697–9

cognitive training exercises 698

cognitive-behavioral therapy
(CBT) 640t

Cohen-Mansfield Agitation
Inventory (CMAI) 469

Colfelt, Robert: Together in the
Dark: Mysteries of Healing 83

colostomy 409

coma 554

Combi-TVA task 340

comics 87

commercial tracking products 216

common stroke syndromes 484

communicative abilities 283

Community Mental Health
Center Act of 1963 708

Compendium of Physical
Activities 206

Compensation-Related
Utilization of Neuronal Circuits
Hypothesis (CRUNCH) 258

competency in the aging adult
723–39

case study 723–5, 738–9

vs. capacity 725–6

complementary therapies 640t

computed tomography
(CT) 123

in AD 451

head: hemorrhage 494f

ischemic stroke 485f

Computer Aided Design
(CAD) 663

Computer Aided Manufacturing
(CAM) 663

crane assisted testing
(CAT) 230, 231

computer games 698

Confusion Assessment Method
(CAM) 554

Congressional Acts targeting
Alzheimer’s disease 710t

Consensus-Based Standards
for the Selection of Health Instruments
(COSMIN) 230–1

constipation 527

contact sports: American football 592–3

contingent negative variation
resolution (CNV-R) 259

contractual capacity (making contracts) 730f

contralateral routing of sound
(CROS) devices 331

Contrast Sensitivity Chart 112

contrast-enhanced magnetic
resonance angiogram of neck 490f, 493f

coprophilia 389

Corsi block-tapping task 258

cortical blindness 305

cortical myoclonus 556

corticobasal degeneration
(CBD) 523, 531, 605

corticobasal syndrome
(CBS) 531

coup injury 601

counterselective attention 343

cranial nerves 112, 113f, 114t

creative writing workshops 85

Creutzfeld-Jakob disease 124,
531, 582

sleep in 625

Crohn’s disease 560

cultural narrative of dementia 95

culture differences in emotions 422–3

Cutie and the Boxer (film) 87, 92

cyclooxygenase (COX)-2 inhibitors 465

daf-2 49

daily activity 205–6

Dali, Salvador: Old Age 87

damage-associated pattern recognition receptors (DAMPs) 51

damaged goods model 298

dark adaptation 302, 303, 303f

DARPA Augmented Cognition Program (AugCog) 218

data collection, large-scale
social, ethical, legal and practical
implications 219

data management 219

data storage and confidentiality 219

date rape drug 390

de Kooning, Willem 87

death, leading causes (2010) 704t

dark adaptation 302, 303, 303f

DARPA Augmented Cognition Program (AugCog) 218

data collection, large-scale
social, ethical, legal and practical
implications 219

data management 219

data storage and confidentiality 219

date rape drug 390

de Kooning, Willem 87

death, leading causes (2010) 704t
DeBaggio, Thomas: *Losing My Mind: An Intimate Look at Life with Alzheimer's* 84

decision-making 260–1
declarative memory 271–7
depth proximal M1 (striatocapsular) 484
default mode network (DMN) 155, 155f, 156, 655
defecography 405
delirium 103, 106, 121t, 553, 554
and dementia, differential diagnosis between 582t
delirium tremens 578
delusional disorder 546
dementia 103, 448–9, 448f
evaluation 450t
PET Imaging 175–83, 176–7f
laboratory evaluation of patients with 451t
cerebrospinal fluid analysis 454t
etiological pathways 704
prevalence rates 703, 703f
*see also* Alzheimer’s disease; Dementia with Lewy Bodies; Parkinson’s disease and other diseases
dementia pugilistica (DP) 591
military veterans 605–6
veterans of high-impact sports 605
Dementia Quality of Life Instrument (DQI) 235, 236
dementia with Lewy Bodies (DLB) 175, 531, 582
visual hallucinations in 547
Demitris, Alex: *Dad’s Not All There Anymore* 87
dementia 103, 448–9, 448f
evaluation 450t
PET Imaging 175–83, 176–7f
laboratory evaluation of patients with 451t
delirium tremens 578
Delis–Kaplan Executive Function System (DKEFS) 139
delusional disorder 546
dementia 103, 448–9, 448f
evaluation 450t
PET Imaging 175–83, 176–7f
laboratory evaluation of patients with 451t
cerebrospinal fluid analysis 454t
etiological pathways 704
prevalence rates 703, 703f
*see also* Alzheimer’s disease; Dementia with Lewy Bodies; Parkinson’s disease and other diseases
dementia pugilistica (DP) 591
military veterans 605–6
veterans of high-impact sports 605
Dementia Quality of Life Instrument (DQI) 235, 236
dementia with Lewy Bodies (DLB) 175, 531, 582
visual hallucinations in 547
dementia 103, 448–9, 448f
evaluation 450t
PET Imaging 175–83, 176–7f
laboratory evaluation of patients with 451t
cerebrospinal fluid analysis 454t
etiological pathways 704
prevalence rates 703, 703f
*see also* Alzheimer’s disease; Dementia with Lewy Bodies; Parkinson’s disease and other diseases
dementia pugilistica (DP) 591
military veterans 605–6
veterans of high-impact sports 605
Dementia Quality of Life Instrument (DQI) 235, 236
dementia with Lewy Bodies (DLB) 175, 531, 582
visual hallucinations in 547
Demitris, Alex: *Dad’s Not All There Anymore* 87
dementia 103, 448–9, 448f
evaluation 450t
PET Imaging 175–83, 176–7f
laboratory evaluation of patients with 451t
cerebrospinal fluid analysis 454t
etiological pathways 704
prevalence rates 703, 703f
*see also* Alzheimer’s disease; Dementia with Lewy Bodies; Parkinson’s disease and other diseases
Demenz, Alex: *Dad’s Not All There Anymore* 87
Dench, Judy 91, 92
depression 106, 542–3
in AD 469
balance and gait impairment in 317
in PD 527
Derek (film) 92
Deru, Bruce 91f
detrusor hyperactivity impaired contractility (DHIC) 391
developmental venous anomaly 494
di Suvero, Mark 87
diabetic retinopathy 298, 302, 303
diagnosis, discussion with patient 125–7
discussing the plan 126
follow-up 126–7
care and the caregiver 127
competency and decision-making 127
electronic medical record 127
monitoring the aging mind and brain outside of the clinic 127
preparation and planning 125
presenting the diagnosis 125–6
Diagnostic and Statistical Manual of Mental Disorders 581
DSM-IV 449, 450
DSM-5® 117
dialysis-induced encephalopathy 560
Dickens, Charles 82
Little Dorrit 83(box)
dietary restriction (DR) 48
differential emotions theory (DET) 424
diffuse axonal injury (DAI) 594, 601
diffusion tensor imaging (DTI) 152, 264, 594
diffusion-weighted MRI 151–6
digital storytelling 93
dignity 694
Discomfot Scale in Dementia of the Alzheimer’s Type (DS-DAT/DS-DAT modified) 637t
discourse processing 283
comprehension 283–4
production 284–5
disequilibrium syndrome 559
disgust 420
Disney, Walt 766
Dizziness Handicap Inventory 328
DNA damage 40, 41
DNA repair mechanisms 41
Do Not Resuscitate (DNR) orders 681
documentaries 92
DOLOPLUS-2 637, 637t
domain mapping 225
Dominantly Inherited Alzheimer Network (DIAN) 467
Donabedian 223–5, 229
Donatello 85
donative capacity (making gifts of funds or property) 730f
donepezil (Aricept) 97, 462t, 463, 464, 621, 679, 712
dopa responsive dystonia (DRD) 535
dorsolateral prefrontal cortex (dlPFC) 355
Down’s syndrome 494, 512
Downton Abbey (TV programme) 91
driving 107, 730f
Index

Drosophila melanogaster 40, 66–7
methuselah mutant 66
toxin accumulation models and oxidative stress models of aging 67
Drosophila models of aging 47, 48
advantages and disadvantages of 62
ataxia-telangiectasia model (ATM) 51
IIS in 49
Sir2 in 50
drug-induced meningitis 562
DSM III-R 448
DSM-5 457, 459
Dunlap-Shohl, Peter:
A Mixed Cursing 87
Dusky v. United States 726
dynamic susceptibility contrast (gadolinium based) 156
dysarthria 527
dysarthric clumsy hand syndrome 491
dysconjugate gaze 114
dysguesia 112
dyskinesia 524
dysphagia 115, 527
dysphonia 115
dystonia 523, 533–6, 556
treatment of 535–6
of vocal cord 535
dystonia-plus 535
DYT1 dystonia 535
Eastwood, Clint 91
efferent vestibular system 321
Ehlers-Danlos syndrome 492
type IV 487, 494
Einstein: equivalence principle 326
El Greco 85
electrodermal response 211, 212
electroencephalography (EEG) 124, 189, 213
outpatient video monitoring data 208
electrocardiogram 211
electromotility 330
electromyography 218
electronic medical record (EMR) 127
electrophysiological measures of age-related cognitive impairment 188–98
functional properties of oscillatory neural activity 190f
review of oscillatory neural activity 189–93
alpha 190–1
theta 191–2
beta 192
delta 192–3
gamma 193
review of stimulus-evoked neural activity 193–6, 194f
N1 195
N2 (N200) 195
P1 193–5
P2 (P200) 195
P3 196
Eliot, George 82
Silas Marner 82
Emerson, Ralph Waldo 82
emotion, contemporary models of aging and 424–9
aging brain model (ABM), 424
cognitive control hypothesis (CCH), 424–5
differential emotions theory (DET) 424
evaluation of 427–9
harmony and dissonance between models 427
level of emotional challenge matters 428
phase of emotion matters 429
type of emotion matters 428
frontal lobe hypothesis (FLH) 426
lifespan theory of control (LTC) 426
selective optimization with compensation model (SOC) 425
selective optimization with compensation—Emotion regulation model (SOCER) 425–6
socioemotional selectivity theory (SET) 425
strength and vulnerability integration (SAVI) model 426–7
emotional empathy 421
emotional function during aging 417–35
age-related change in the experience of emotions 419–21
complexity of emotion 420–1
discrete negative emotions 419
intensity of emotions 420
positive emotions 420
social cognitive and self-conscious emotions 421
culture differences 422–3
environmental change in late adulthood 423
functional variability associated with aging 422
individual differences 422
personality differences 423
positivity effect 418–19
sex differences 422
empathy 421
encephalitis 390
encephalopathy 103, 553–83, 555t
autoimmune 564–70
anti-NMDA receptor antibody encephalitis 568
anti-VGKC-complex antibody encephalitis 568–9, 569f
differential diagnosis of autoimmune/steroid-responsive encephalopathies 566–7t
Hashimoto’s encephalopathy 569–70
other autoimmune encephalitides 570
paraneoplastic limbic encephalitis 565
clinical manifestations 553–6
altered content of consciousness 554
meningeal signs 554
movement disorders 556
reduced level of consciousness or arousal 553–4
seizures 555
definition 553
dementia and 581–3
delirium vs. 581–2
rapidly progressive degenerative dementias 582–3
drug-Induced 578–81
endocrine-metabolic 556–61
infectious 561–4
acute bacterial meningitis 561–2
viral meningoencephalitis 562–3
sepsis-associated encephalopathy 563–4
toxic 576–8
vascular encephalopathies 570–6
encephalopathy-associated tremor 556
end-of-life (EOL) care 680
cosinophilic granulomatosis with polyangiitis (p-ANCA) 573
epidural empyema 562
epilepsia partialis continua 557, 570
epilepsy 390
FDG 173, 174f
PET imaging 173–5
Epstein-Barr virus 562, 563
EQ-5D 239–40
cognitive dysfunction 396–401
background 396
diagnosis of 397–8
diagnostic studies 398
history 397
physical examination 397
priapism 401
risk factors 396
treatment 397t, 400–1
devices 400
intracavernosal therapy 400–1
oral agents 400
penile prosthesis 401
surgical therapy 401
testosterone 401
transurethral therapy 400
vascular procedures 401
cognition, anatomy and physiology of 396–7
error-prone ligation mechanism 41
estrogen replacement therapy 465–6
ethanol 389
ethics
advanced dementia and the brain at the end of life 696
brain death 696
mild to moderate dementia 695–6
neuroscience research on aging 696–7
preclinical stage and mild cognitive impairment 694–5
progressive dementia 694–7
research involving biomarkers for dementia 697
ethylene glycol poisoning 577–8
EUROHIS-QOL-8 237, 238
EuroQOL measure 239
event-related potentials (ERPs) 124, 340
evolutionary theories of aging 38–40
exafference 325
Examination in the Professional Practice of Psychology (EPPP) 140
excitotoxic injury 602
executive function 255–66
aging-related diseases and 264–5
assessment and management of deficits in aging 265–6
definition 255–6
dimensions 256t
identifying the key aspects of, in older persons 261–4
lifespan changes in 256–8
schematic representation of 257f
exercise 64, 652t
exhibitionism 389
Experience Sampling Method (ESM) 208–9
expressive aphasia 116
expressive writing 85
extreme delta brush pattern 568
extremely long-lived proteins (ELLPs) 45
eye movement tracking techniques 218
eye movements 112–14, 211, 213, 343–5
eye, structural changes with aging 296–8
eye-head neurons (EHs) 324
Fabry disease 488, 512
Facebook 216
facial expression 213
facial strength and sensation 114
Index

failure to execute 105–6
fairness perception of older workers 754
falls 317, 318
falls in the elderly 373
family caregiving 675–6
Farmer, Joyce: Special Exits: A Graphic Memoir 87
fear 419–20
fecal incontinence (FI) 401–9
clinical evaluation of fecal incontinence 403–4
clinical grading system for fecal incontinence 403t
drugs causing 402t
investigations 404–5
anal endosonography 405
balloon expulsion test 405
clinical utility of tests for fecal incontinence 405
defecography 405
pudendal nerve terminal motor latency (PNTML) 405
management 406–9
biofeedback therapy 406–7
injectable bulking agents 407
pharmacotherapy 406
spinal cord injury 408–9
supportive therapy 406
surgery 407–9
overview 401–2
pathophysiology and etiology 402–3
physical examination 404
prevalence and impact on life 402
Federal policy on dementia 708–12
fibromuscular dysplasia 488, 492
film 91–3
aging and artistic creativity 92
aging mind on screen 91–2
dementia film 92
short films 92
therapeutic uses of, for older adults 92–3
financial capacity 730f
financing care 682, 707f
fine digit motor tasks 367
fine hand motor function 368–73, 368f, 370f, 371f
FitBit 216, 220
FLAIR, axial 150f
floccular target neurons (FTNs) 324
focal dystonias 535
Folstein Mini-Mental Status Exam 117
forme fruste 562
FOXO transcription factor 48
fractional anisotropy (FA) 152
Franzen, Jonathan
Corrections, The 83
“My Father’s Brain” 84
freezing of gait 526–7
Friedan, Betty 82
frontal executive theory of aging 262–3
frontal lobe executive dysfunction, falls and 317
frontal lobe hypothesis 286, 426
frontal lobe lesions 107
frontotemporal dementia (FTD) 103, 107, 120t, 175, 531, 550, 582, 605
sleep in 625
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 66
frontotemporal lobar degeneration (FTLD) 264, 265
frotteurism 389
functional magnetic resonance imaging (fMRI) 123, 154, 189
functional movement disorders 538–9
gait examination 111
Galantamine (Razadyne; Razadyne) 712
galantamine (Reminyl) 462t, 463, 464, 712
galvanic skin response (GSR) 211, 212
gantenerumab 467
Garcin, Gilbert 87
gaze behavior 344
gender
frontal lobe and brain aging and 263–4
labour market 747–8
generalized anxiety disorder (GAD) 547, 548
generalized seizures 555
generalized tonic-clonic status epilepticus 555
generativity 28
Genova, Lisa: Still Alice 83
George, Daniel E. 95
Geriatric Depression Scale (GDS) 85, 139
Gertsmann’s syndrome 306t
Gervais, Ricky 92
Get Into Reading 85
Get Low (film) 91
Girl with the Dragon Tattoo (film) 91
Glasgow Coma Scale 594, 595t
Glasgow Outcome Scale (GOS) 571
glaucoma 298, 301, 302, 303, 308
angle-closure 298
Glanzmann’s thrombasthenia 47
global positioning system (GPS) data 211
global switch costs 351
glycerophosphocholine (GPC) 154
glycerophosphoethanolamine (GPE) 154
Go/No-Go task 196, 261, 348
goal management training (GMT) approach 265
goal-oriented processes 255
Index

Godard, Jean-Luc 91

Golden Girls, The (film) 91

gonorrea 390

Google 219

Google Glass 216

Grabos, Thomas: Life in the Balance 84

gradient recalled echo (GRE) 149, 494

granulomatosis with polyangiitis (c-ANCA) 573

graphesthesia 110

graphic narratives 87

Greedy for Life (documentary) 92

Greenberger, David: Duplex Planet, The 87

Gross v. FBL Financial Services, Inc. 754

guilt 421

Haemophilus influenzae 562

hallucinations 106

auditory 106, 547

musical 547

see also visual hallucinations

Halstead–Reitan Neuropsychological Battery (HRNB) 131–2

Harker, Joshua: “Twenty-First Century Self-Portrait” 95

Harold and Maude (film) 91

Hashimoto’s encephalopathy 569–70

Hawthorne Effect 205

Hayflick limit 41

Hazen Paper Co. v. Biggins 753

Head Over Heels (film) 91, 91f

head-impulse-test (HIT) 115

health, WHO definition 19

Health Outcomes, Planning, and Education for Alzheimer’s Act 710

health-related quality of life (HRQOL) measures 227–8, 228f,

229–30, 236

healthy aging 19–20, 653–5

hearing 115, 315–16

hearing loss 115

heartbeat, rate and interbeat interval 212

helicotrema 328

hemiballism 538, 556

hemichorea-hemiballism 557

hemispheric asymmetry

reduction in older adults (HAROLD) model 154, 258, 259

hemispherical encoding retrieval asymmetry (HERA) theory 259

hemorrhage

head 494f

intracerebral 487

subarachnoid 484, 487

hemorrhagic stroke 487, 492–5, 493t

hepatic encephalopathy 558–9

heroin 492

herpes simplex encephalitis 564f

herpes zoster 114, 390

heteroplasmy 43

HHV-6 563

Hitchcock, Alfred 91

HIV 390, 562

HIV encephalitis 390

Hoffman, Philip Seymour 92

Holter monitors 216

Home Health Care and Alzheimer’s Disease Act of 1990 710

home healthcare 677

homologous recombination 41

homonymous hemianopia with preserved temporal crescent cerebral achromatopsia 305

homonymous scotoma 305

homosexuality 389

Hoover’s sign (leg paresis) 539

Hopkins Verbal Learning Test (HVLT) 135, 136

Hopkins, Anthony 91

Horner’s syndrome 494

hospice services 677

hot cross bun sign 531

Hot in Cleveland (film) 91

Houston model 140

HRQOL 227–8, 228f, 229–30, 236

HSV-1 562

HSV-2 562, 563

HTLV-I infections 390

hubristic pride 421

human factors engineering 662–70

cognitive considerations in the design of products and equipment and tasks 666–8

designing training and instructional programs for older adults 668–9

overview 664

performance assessment and evaluation 669–70

user-centered design 664–5

human soul 691(box)

humanistic perspectives 78–97

Huntington’s disease 39, 121t, 454, 523, 536

mitochondrial dysfunction 43

Hussey, Tom: “Reflections” series 87

Hutchinson–Gilford Progeria Syndrome (HGPS) 68

progerin in 63

hydrocephalus ex vacuo 607

hypercalcemia 558

hypercapnic encephalopathy 560

hyperemesis gravidarum 560

hyperglycemia 557
hyperkinesia (excessive movements) 524
hyperkinetic disorders 533–9
hypermantremia 557
hyperthyroidism 558
hypocalcemia 557
hypoglycemia 556
hypokinesia 524
hypokinetic dysarthria 527
hypokinetic movement disorders 525–9
hyponatremia 557
hypophonia 527
hyposmia 112
hypothyroidism 558
ICD-10-CM 596t
Ignatieff, Michael: Scar Tissue 83
illustration and painting 87
impotence 390
Improving Dementia Care Treatment for Older Adults Act of 2012 710
incontinence 107, 390
CNS substrates of genitourinary dysfunction 389–91
infectious vasculitis 562
infective endocarditis 484
Inferior division MCA 484
inflammatory cerebral amyloid angiopathy 575–6, 576f
instrumental activities of daily living (IADL) 673, 674, 678
insulin and insulin-like growth factor (IGF) receptors mediated signaling pathway (IIS) 48, 49
Integrated Perspective of Aging and Emotion (IPAE) 429–35, 432f
new perspective 429–35
age-related strengths and weakness affect emotion generation 430–3
appraisal 432
attention 432
response 433
age-related strengths and weakness affect emotion generation 433–5
attention deployment 434
cognitive change 434
response modulation 434–5
situation modification 433
situation selection 433
linking the IPAE to existing models 435
overview 429–30
processing model of emotion regulation 429
interindividual variability 663
International Statistical Classification of Diseases and Related Health Problems ICD-10 117
internet users 23
Intracerebral hemorrhages 487
intra-individual variability 663
Iowa gambling task (IGT) 260
Iowa-Benton approach 132, 133–4t
IQ 135, 460
Iron Lady, The (film) 92
Iron Lady, The (film) 92
ischemic injury 602
ischemic penumbra 500
ischemic stroke 484, 488–92
isometric ankle plantarflexor torque 375f
item response theory (IRT) 230, 231
James Bond film franchise 91
jealousy 389
Jimmo v. Sebelius 712
JNK (c-Jun N-terminal kinase) 48
Jones, James Earl 91
Judgment of Line Orientation Test (JLO) 138
Kernig’s sign 554
Klawans, Harold: Defending the Cavewoman: And Other Tales of Evolutionary Neurology 84
Klüver-Bucy syndrome (KBS) 390
knee-jerk reflex 362
Kokmen Short Test of Mental Status (KSTME) 117, 118f, 450, 459
Kollwitz, Käthe 87
Korsakoff’s psychosis 561
Korsakoff’s syndrome 572
Kurosawa, Akira 91
Kusama, Yayoi 87
labor market
gender and 747–8
participation after Great Recession 744–7, 745f, 746f
lacunar infarcts 510
lacZ reporter gene 40
Lance-Adams syndrome 538, 571
Landolt-rings 300
language 137–8, 270, 278–85
age-related changes in 280–5
basic properties and neural correlates 279
comprehension 137
discourse processing 283
comprehension 283–4
production 284–5
examination of 115–16
fluency 137
interactive activation model of 279
lexical processing 280–2
recognition 280–2
retrieval 282
memory and, interactions between 287–9
models of cognitive aging applied to 285–7
naming 138
neural correlates of processes 275f
repetition 137
sentence processing 282–3
comprehension 282–3
production 283
taxonomy of 281f
Lansbury, Angela 91
Last Station, The (film) 92
Late Quartet, A (film) 92
lateral vestibular nuclei (LVN) 321
Laurence, Margaret: Stone Angel, The 83
Law, Valerie: “Invisible Brain” (All That Lives) 84
Lawrence, Jacob 87
Layton, Elizabeth (“Grandma”) Stroke 87, 88f
Leavitt, Sarah: Tangles: A Story About Alzheimer’s, My Mother, and Me 87
LeGuin, Ursula K. 82
lesbian, gay, bisexual, and transgender (LGBT) older adults 93
leucocyte telomere length (LTL) 42
leukoaraiosis 147, 150, 452, 510
level-of-awareness hypothesis 349
Lewy body dementia (LBD) frequently associated with REM sleep behavior disorder (RBD) 622
sleep in 622, 624
Lewy body disease 103, 120t
lexical processing 280–2
recognition 280–2
retrieval 282
lexical traffic jams 282
life review 85
lifespan theory of control (LTC) 426
lifespans 37
Likert scales 231
linguistic abilities 283
LinkedIn 216
lipohyalinosis 491
Listeria monocytogenes 562
literature and writing 82–5
local switch costs 351
long term potentiation (LTP) impairment in the dentate gyrus 64
long-term care Ombudsman program 681
long-term care services 674–5, 674f
long-term memory 272
Lord of the Rings (film) 91
love 389
Lowenberg, Ina 87
lower cranial nerves 115
lower limb motor function in healthy aging 373–81
central coordination of standing balance 377–80, 378f, 379f, 380f
effects of age on brain and lower extremity function during balance and gait 380–1, 380f
falls in the elderly 373
gait on even and uneven surfaces 376–7, 377f
importance of lower limb function in healthy aging 373
physical capacities and recovery from perturbations 374–5
recovering balance with a single step 375
MacArthur Competence Assessment Tool for Treatment 735
macropsia 307t
macular degeneration 307
macular sparing homonymous hemianopia 305
magnetic field correlation (MFC) 149
magnetic resonance imaging (MRI) 123, 189
in AD 451
of brain 485f, 492f
perfusion-weighted 156
magnetic resonance spectroscopy (MRS) 152–4, 460
magnetic resonance venogram 487f
magnetoencephalography (MEG) 124
man in the barrel syndrome 571
Marfan syndrome 488, 492
marijuana 389
Marks v. Loral Corp. 753
Matisse, Henri 87
McEwan, Ian 91
Saturday 83
MDMA (Ecstasy) 389
Meacham v. Knolls Atomic Power Laboratory 754
mean diffusivity (MD) 152
mean-level change 423
mechanistic target of rapamycin (mTOR) 48, 49
medial vestibular nuclei (MVN) 321
Medicaid 677, 709, 711, 712, 716
medical assessment of the aging mind and brain 103–27
diagnosis 117–25
differential diagnosis 117
history 104–8
testing and investigations 117–25
consultations 125
CSF and biomarkers 124
electroencephalography 124
genetic testing 125
imaging 123–4
laboratory and blood testing 123
neuropsychological testing 123
Medicare 677, 709, 711, 716
Medicare Accountable Care Organizations 716
Medicare Shared Savings Plan (MSSP) 716
medications that affect mental status and cognition 107, 108t
meditation 698
memantine (Namenda) 464, 679, 712
memoir 84
Memories in the Making© 90
memory 105, 270, 271–8
language and, interactions between 287–9
long-term 272
models of cognitive aging applied to 285–7
neural correlates of 275f
nondeclarative 271–6, 277
taxonomy of 272f
Memory Batteries 136
Ménière’s disease 330
meningitis
aseptic (lymphocytic) 562
bacterial, acute 561–2
chemical 562
drug-induced 562
viral 562–3
mental retardation 390
mental status examination 116–17
metabolic equivalents of task (MET) 652t
metabolic syndrome 488
metamorphopsia 307t
methanol poisoning 577–8
Michelangelo 85
microaggressions 751
microinequities 751
micropsia 307t
middle cerebral artery (MCA) 484
migraine headache 328
mild cognitive impairment 103, 456–62, 663, 694–5
amnestic and nonamnestic, single and multiple domain 458f
clinical criteria 457–9, 458f
conceptual framework 456
CSF biomarkers 460–1, 471t
evaluation 459–60
exercise in 655–6
flow diagram for diagnosing 457f
genetics 461
neuroimaging 460
neuropathology 461
neuropsychological testing 460
Sleep 622
military metaphors 95
Mini-Mental State Examination (MMSE) 450, 459, 460, 554
Minimum Data Set (MDS) 681
Minnesota Multiphasic Personality Inventory (MMPI-2) 139, 724
Symptom Validity Scale (Fake Bad Scale) 139
Missing Alzheimer’s Disease Patient Alert
mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) 488, 512
mitogen-activated protein kinase (MAPK) signaling pathway 46
mitophagy 43
mixed urinary incontinence 391
mnemonic strategies 698
mobile phone data 205
Mobilization-Observation- Behavior-Intensity- Dementia (MOBID and MOBID-2) Pain Scale 637, 637t
Modified Mini-Mental State (3MS) 450
modified Rankin Scale (mRS) 507, 509
Molecular Imaging and Contrast Agent Database (MICAD) 168, 169f
Mollaret’s meningitis 562
monoballism 538
monocular temporal crescent 305
Montreal Cognitive Assessment (MoCA) 117, 119f, 265, 450, 459, 554
mood measures 139
Morris, Hayley 92, 93f
Morrison, Toni 82
Morvan syndrome 569
motor examination 109–10
motor functions and mobility 362–81
age-related changes in brain function during motor tasks 366
age-related changes in brain neurochemistry and motor function 365–6
Index

age-related changes in brain structure and motor function 365
avoiding age-related declines in movement control 366–7
lower limb motor function in healthy aging 373–81
upper limb motor function in healthy aging 363–5, 364f
motoric cognitive risk syndrome (MCR) 317
mouse and rat model of pathological aging 62t
movement disorders 523–39 classification of 524t
movements, human and energy expenditure, classification and tracking 206–7
inside–inside, inside–outside, and outside–inside 211
Moyamoya disease 492
mTORC1 49–50
mTORC2 49–50
multifocal axonal injury 594
multi-infarct dementia 510, 514
Multilingual Aphasia Examination 137
Sentence Repetition test 137
Visual Naming test 138
multiple memory systems 271–6
multiple sclerosis 264
sexual dysfunction in 390 sleep in 625
multisystem atrophy (MSA) 107, 523, 527, 530
multitasking 351
mumps 562
Munro, Alice 82
"Bear Came Over the Mountain, The" 83, 92
Murder, She Wrote (film) 91
Murdoch, Iris 82, 84, 92
Mus musculus model of aging 67–70
musical hallucinations 547
musician’s cramp 535
Myerson’s sign 111, 554
myoclonic status epilepticus 571
myoclonus 538, 556
myoclonus, chronic posthypoxic 538
myxedema coma 558
NAD-dependent protein deacetylase 48
National Alzheimer’s Project Act of 2010 710, 715
National Eye Institute Visual Function Questionnaire (NEI-VFQ) 307–8
National Institutes of Health Stroke Scale (NIHSS) 507–9, 508t
National Mental Health Act of 1946 708
near infrared spectroscopy (NIRS) 124, 213
Nebraska (film) 91, 92
necrophilia 389
Neel, Alice 87
negative myoclonus 556
Neisseria meningitidis 562
NEPSY-2 256
nerve growth factor (NGF) 47
neural presbycusis 331
Neuro Paradigm 94–6
neurocognitive impairment, major 449
neuroculture 95–6, 690
neurodegenerative disorders 390
neurodegenerative proteinopathies 605
neurodevelopmental disorders 390
neuroethics of aging 689–99
neurofibrillary tangles (NFTs) 63, 455, 456
neurofibromatosis 488
neurohumanities 94
neuroleptic malignant syndrome 579–80
neurologic examination 109–17, 109f
Neuropsychiatric Inventory (NPI) 469
(NPI-Q) 469
neuropsychological assessment of aging individuals 130–45
case studies 140–5
domains of assessment 135–9
effort and exaggeration 139
executive functions 138–9
intellect 135
language 137–8
memory 135
memory batteries 136–7
mood and personality 139
remote memory 136
verbal memory 135–6
visual functions 138
visual memory 136
fixed batteries and flexible batteries 131
models of assessment 131–5
training and credentialing in 139–40
neuropsychometrics, formal 123
neuroscientific turn 94
neuroskepticism 78, 95
New York City Museum of Modern Art, Meet Me at MoMA program 89
NFL cohort study 599
NF-κB 51
NIH Roadmap for Medical Research 231
Nine-point framework for assessment 728f
N-methyl-D-aspartate (NMDA) 679
Index

Non-Communicative Patient’s
Pain Assessment
Instrument
(NOPPAIN) 637, 637t
noncompliance 674
nonconvulsive status
epilepticus
(NCSE) 555
nondeclarative memory
271–6, 277
non-exercise
activity thermogenesis
(NEAT) 652t, 653
nonhomologous end joining
(NHEJ) 41
nonparaneoplastic limbic
encephalitis 565
nonpenetrating (closed)
TBI 601
non-rapid eye movement
(NREM) sleep 619
nonsteroidal anti-inflammatory
drugs (NSAIDs) 465
normal aging 448, 448f
brain morphologic,
chemical and
physiologic changes
in 146–55
normal pressure hydrocephalus
(NPH) 107, 121t,
390, 532
novels, aging mind in 83
nucleotide excision repair
systems (NER) 41
Nuremberg Code 726
Nursing Home Reform Act
(NHRA) of
1987 713
nutrition 698
nymphomania 389
O’Keeffe, Georgie 87
obstructive sleep apnea (OSA)
622, 623–4
obtundation 554
occlusive atherosclerotic
disease 484
Odyssey 92
Older Americans Act (OAA)
709, 712
older driver response 215f
Older Person Quality of Life
Questionnaire
(OPQOL) 241–2, 245
OPQOL-13 242
OPQOL-35 242
olfactory dysfunction 112
olivocochlear efferents 330
olivopontocerebellar atrophy
see multisystem
atrophy (MSA)
Olmstead v LLC 708
onanism 389
open-ended questions 116
opioid analgesic overdose 578–9
optical coherence tomography
(OCT) 112
optical computer recognition
(OCR) 213
optokinet nystagmus
(OKN) 321
orgasm 390
oromandibular dystonia
(OMD) 535
Orwell, George: 1984 219
osteopenia 327
osteoporosis 327
overflow urinary incontinence
391–2
overpowering hypothesis 428
oxidative stress theory 63, 602
p16INK4a/pRb pathways 46
p53/p21 pathway 46
pain, dementia and 628–42
detection and assessment of
636–9, 637t, 638t
epidemiology of 629–30
guidelines for assessing pain
in dementia 638–9
management 639–42
nonpharmacologic
640, 640t
pharmacologic 641
observational approaches to
the assessment of
pain in dementia
636–8, 637t
pain perception and
processing 632–5
pain processing in ad
632–4
pain processing in other
types of
dementia 635
persistent, behavioral and
psychosocial impacts
of 629–31
Pain Assessment Checklist for
Seniors with Limited
Ability to
Communicate
(PACSLAC) 637, 637t, 638
Pain Assessment Checklist for
Seniors with Limited
Ability to
Communicate
(PACSLAC-II) 637t, 638
Pain Assessment for the
Dementing Elderly
(PADE) 637, 637t
Pain Assessment in Advanced
Dementia (PAINAD)
637, 637t, 638
Pain Assessment in
Noncommunicative
Elderly Persons
(PAIN) 637t
Pain Assessment in the
Communicatively
Impaired
(PACI) 637t
pain scales 108
papavarian in erectile
dysfunction 401
paraballism 538
paralinguistic speech cues 284
paraneoplastic limbic
encephalitis 565
<table>
<thead>
<tr>
<th>Term</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>paranoid personality disorder</td>
<td>550</td>
</tr>
<tr>
<td>paraphrenia</td>
<td>546</td>
</tr>
<tr>
<td>paraquat</td>
<td>69</td>
</tr>
<tr>
<td>parasagittal meningioma</td>
<td>390</td>
</tr>
<tr>
<td>Parkinson’s disease (PD)</td>
<td>103, 120t, 264, 523, 525, 599, 656</td>
</tr>
<tr>
<td>animal models of major genetic mutations</td>
<td>63t</td>
</tr>
<tr>
<td>as major area of research in nonhuman primates</td>
<td></td>
</tr>
<tr>
<td>clinical manifestations causes</td>
<td>316</td>
</tr>
<tr>
<td>clinical features of 526t</td>
<td></td>
</tr>
<tr>
<td>cognitive and psychiatric manifestations</td>
<td>527</td>
</tr>
<tr>
<td>dysautonomia</td>
<td>527</td>
</tr>
<tr>
<td>etiology and pathogenesis</td>
<td>528</td>
</tr>
<tr>
<td>medical treatment: 528–9</td>
<td></td>
</tr>
<tr>
<td>motor symptoms</td>
<td>526–7, 529f</td>
</tr>
<tr>
<td>non-motor symptoms</td>
<td>529–30</td>
</tr>
<tr>
<td>depression</td>
<td>529–30, 545</td>
</tr>
<tr>
<td>dementia</td>
<td>530</td>
</tr>
<tr>
<td>psychosis</td>
<td>530</td>
</tr>
<tr>
<td>orthostatic hypotension</td>
<td>530</td>
</tr>
<tr>
<td>pathology</td>
<td>528</td>
</tr>
<tr>
<td>sensory manifestation</td>
<td>528</td>
</tr>
<tr>
<td>sleep disorders</td>
<td>527</td>
</tr>
<tr>
<td>surgical management</td>
<td>529</td>
</tr>
<tr>
<td>cognitive dysfunction in early 527</td>
<td></td>
</tr>
<tr>
<td>DNA strand breakage</td>
<td>41</td>
</tr>
<tr>
<td>gait impairment in 111, 317</td>
<td></td>
</tr>
<tr>
<td>Lewy bodies in 44, 63</td>
<td></td>
</tr>
<tr>
<td>mitochondrial dysfunction</td>
<td>43</td>
</tr>
<tr>
<td>MPTP</td>
<td>70</td>
</tr>
<tr>
<td>sleep disorder in 622–3</td>
<td></td>
</tr>
<tr>
<td>visual hallucinations in 546–7</td>
<td></td>
</tr>
<tr>
<td>α-synuclein models</td>
<td>45</td>
</tr>
<tr>
<td>parkinsonism</td>
<td></td>
</tr>
<tr>
<td>differential diagnosis of 525f</td>
<td>532</td>
</tr>
<tr>
<td>parkinsonism-hyperpyrexia syndrome</td>
<td>579</td>
</tr>
<tr>
<td>Parkinson-plus syndromes</td>
<td>523, 530–1</td>
</tr>
<tr>
<td>participatory reading and writing programs</td>
<td>85</td>
</tr>
<tr>
<td>patellar reflex</td>
<td>362</td>
</tr>
<tr>
<td>pathologic reflexes</td>
<td>110–11</td>
</tr>
<tr>
<td>patient H.M. (memory case study)</td>
<td>273</td>
</tr>
<tr>
<td>Patient Protection and Affordable Care Act of 2010</td>
<td>712, 716</td>
</tr>
<tr>
<td>patient-reported outcomes (PROs)</td>
<td>225</td>
</tr>
<tr>
<td>Patient-Reported Outcomes Measurement Information System (PROMIS)</td>
<td>231–2</td>
</tr>
<tr>
<td>pedophilia</td>
<td>389</td>
</tr>
<tr>
<td>pelvic muscle exercises</td>
<td>394</td>
</tr>
<tr>
<td>Penelope: The Documentary</td>
<td>92</td>
</tr>
<tr>
<td>penetrating injuries</td>
<td>600–1</td>
</tr>
<tr>
<td>penile erection, mechanism of</td>
<td>399f</td>
</tr>
<tr>
<td>penile prosthesis</td>
<td>401</td>
</tr>
<tr>
<td>penile venous return</td>
<td>398f</td>
</tr>
<tr>
<td>Penny, Evan</td>
<td></td>
</tr>
<tr>
<td>Old Self: Variation #1</td>
<td>88f</td>
</tr>
<tr>
<td>Old Self: Variation #2</td>
<td>89f</td>
</tr>
<tr>
<td>Old Self, Young Self series</td>
<td>87</td>
</tr>
<tr>
<td>(2011)</td>
<td></td>
</tr>
<tr>
<td>Pittsburgh Compound B (PiB)</td>
<td>452</td>
</tr>
<tr>
<td>planar cell polarity (PCP)</td>
<td>319</td>
</tr>
<tr>
<td>Plato</td>
<td>204</td>
</tr>
<tr>
<td>Plummer, Christopher</td>
<td>91, 92</td>
</tr>
<tr>
<td>PMOD’s Alzheimer’s Discrimination tool (PALZ)</td>
<td>177</td>
</tr>
<tr>
<td>poetry and aging mind</td>
<td>83–4</td>
</tr>
<tr>
<td>political economy</td>
<td>748–51, 750f</td>
</tr>
<tr>
<td>population aging</td>
<td>702</td>
</tr>
<tr>
<td>Portland Digit Recognition Test</td>
<td>139</td>
</tr>
<tr>
<td>positive myoclonus</td>
<td>556</td>
</tr>
<tr>
<td>positive visual phenomena</td>
<td>306t</td>
</tr>
</tbody>
</table>

Index
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>positron emission tomography (PET)</td>
<td>123, 157, 164–84, 165f, 460</td>
</tr>
<tr>
<td>in Alzheimer’s Disease (AD) and Dementia</td>
<td>175–83, 176–7f, 452</td>
</tr>
<tr>
<td>amyloid imaging 179–82, 180t, 181t, 181f</td>
<td>164–84, 165f, 460</td>
</tr>
<tr>
<td>appropriate use criteria</td>
<td>182–3f</td>
</tr>
<tr>
<td>glucose metabolism in dementia</td>
<td>177–8f</td>
</tr>
<tr>
<td>role of imaging in dementia</td>
<td>175–83, 176–7f, 452</td>
</tr>
<tr>
<td>Tau imaging</td>
<td>180t, 181t, 181f</td>
</tr>
<tr>
<td>definitions of imaging terms</td>
<td>166–7t</td>
</tr>
<tr>
<td>clinical/research uses of</td>
<td>168–73</td>
</tr>
<tr>
<td>cerebral blood flow imaging: [15o]water 168–71, 171f</td>
<td></td>
</tr>
<tr>
<td>cerebral metabolism imaging: [18F] fluorodeoxyglucose (FDG)/Fludeoxyglucose F18 172–3, 172f</td>
<td></td>
</tr>
<tr>
<td>epilepsy Imaging</td>
<td>173–5, 174f</td>
</tr>
<tr>
<td>principles of 164–8</td>
<td></td>
</tr>
<tr>
<td>positron emission 165</td>
<td></td>
</tr>
<tr>
<td>positron-emitting radionuclides</td>
<td>164, 165t</td>
</tr>
<tr>
<td>positron-emitting radiopharmaceuticals</td>
<td>168, 169t</td>
</tr>
<tr>
<td>postcardiac arrest</td>
<td></td>
</tr>
<tr>
<td>encephalopathy 570–2, 572f</td>
<td></td>
</tr>
<tr>
<td>postanoxic myoclonus 571</td>
<td></td>
</tr>
<tr>
<td>posterior inferior cerebellan artery (PICA) 328</td>
<td></td>
</tr>
<tr>
<td>posterior cerebral artery (PCA) 484</td>
<td></td>
</tr>
<tr>
<td>posterior insular vestibular cortex (PIVC) 321</td>
<td></td>
</tr>
<tr>
<td>posterior reversible encephalopathy syndrome (PRES) 572–3, 574f</td>
<td></td>
</tr>
<tr>
<td>postresuscitation</td>
<td></td>
</tr>
<tr>
<td>encephalopathy 570–2, 572f</td>
<td></td>
</tr>
<tr>
<td>post-traumatic stress disorder (PTSD) 209, 548, 605</td>
<td></td>
</tr>
<tr>
<td>power of attorney (POA) 127</td>
<td></td>
</tr>
<tr>
<td>PRACTICAL mnemonic 245</td>
<td></td>
</tr>
<tr>
<td>prednisone 465</td>
<td></td>
</tr>
<tr>
<td>premenstrual syndrome 389</td>
<td></td>
</tr>
<tr>
<td>presbycusis 115, 284, 330, 331</td>
<td></td>
</tr>
<tr>
<td>presbyopia 296</td>
<td></td>
</tr>
<tr>
<td>priapism 401</td>
<td></td>
</tr>
<tr>
<td>pride 421</td>
<td></td>
</tr>
<tr>
<td>primary central nervous system (CNS) vasculitis 492, 573–5, 574f</td>
<td></td>
</tr>
<tr>
<td>primates model of aging 70–1 advantages and disadvantages of 62t</td>
<td></td>
</tr>
<tr>
<td>priming 276, 279</td>
<td></td>
</tr>
<tr>
<td>prion diseases 605</td>
<td></td>
</tr>
<tr>
<td>prionoid mechanisms 605</td>
<td></td>
</tr>
<tr>
<td>PRISM 665, 666, 667, 670</td>
<td></td>
</tr>
<tr>
<td>procedural memory see nondeclarative memory</td>
<td></td>
</tr>
<tr>
<td>program optimization software 663</td>
<td></td>
</tr>
<tr>
<td>progressive aphasia 265</td>
<td></td>
</tr>
<tr>
<td>progressive multifocal leukoencephalopathy (PML) 390</td>
<td></td>
</tr>
<tr>
<td>progressive non-fluent aphasia (PNFA) 265</td>
<td></td>
</tr>
<tr>
<td>progressive supranuclear palsy (PSP) 523, 527, 530, 531, 605</td>
<td></td>
</tr>
<tr>
<td>falls in 317</td>
<td></td>
</tr>
<tr>
<td>prompted voiding 394</td>
<td></td>
</tr>
<tr>
<td>proprioception 110</td>
<td></td>
</tr>
<tr>
<td>prosopagnosia 305, 306t, 484</td>
<td></td>
</tr>
<tr>
<td>Protecting Older Workers Against</td>
<td></td>
</tr>
<tr>
<td>Protection Act (POWADA) 755</td>
<td></td>
</tr>
<tr>
<td>protein-dysfunction theories 63</td>
<td></td>
</tr>
<tr>
<td>proton spectrum in normal control 153f</td>
<td></td>
</tr>
<tr>
<td>PSEN1 gene 125</td>
<td></td>
</tr>
<tr>
<td>PSEN2 gene 125</td>
<td></td>
</tr>
<tr>
<td>psychiatric disorders 541–50</td>
<td></td>
</tr>
<tr>
<td>case studies 541–2</td>
<td></td>
</tr>
<tr>
<td>psychogenic (nonepileptic) seizures 208</td>
<td></td>
</tr>
<tr>
<td>psychogenic movement disorders 538–9</td>
<td></td>
</tr>
<tr>
<td>psychosis 121t, 545–50</td>
<td></td>
</tr>
<tr>
<td>in AD 469</td>
<td></td>
</tr>
<tr>
<td>public health 702–16</td>
<td></td>
</tr>
<tr>
<td>future of 715–16</td>
<td></td>
</tr>
<tr>
<td>challenges presented by persons with dementia 704–6</td>
<td></td>
</tr>
<tr>
<td>policy context 706</td>
<td></td>
</tr>
<tr>
<td>political ideology and dementia policy 706–8</td>
<td></td>
</tr>
<tr>
<td>pudendal nerve terminal motor latency (PNTML) 405</td>
<td></td>
</tr>
<tr>
<td>punch drunk syndrome see dementia pugilistica</td>
<td></td>
</tr>
<tr>
<td>pupilometry 213</td>
<td></td>
</tr>
<tr>
<td>pyloric stenosis 560</td>
<td></td>
</tr>
<tr>
<td>QHOOQOL-BREF 237</td>
<td></td>
</tr>
<tr>
<td>QOL Measures Specifically for Older Adults 241–4</td>
<td></td>
</tr>
<tr>
<td>QOL-P 236</td>
<td></td>
</tr>
<tr>
<td>QUALIDEM 235</td>
<td></td>
</tr>
<tr>
<td>Quality Adjusted Life Years (QALYs) 239</td>
<td></td>
</tr>
<tr>
<td>quality of life assessment</td>
<td>223–46</td>
</tr>
<tr>
<td>development of 225–6</td>
<td></td>
</tr>
<tr>
<td>Donabedian legacy 223–5, 229</td>
<td></td>
</tr>
<tr>
<td>FDA’s patient-reported guidelines for industry methods and measurements 232–3, 233f, 234t</td>
<td></td>
</tr>
</tbody>
</table>
Selected Generic Preference or Utility Measures 239–41
Selected Generic QOL and HRQOL Measures 237–9
Special considerations for older adults 235–7
WHO perspective 226–7
Quality of Life for Dementia (QOL-D) scale 235
Quality of Life in Alzheimer’s Disease Questionnaire 235
Quality of Well Being measure 239
Queen, The (film) 91
questions, open ended 104t
Raichle, Jean 89
Blue Eyes 90f
Falling 90f
rank-order consistency 423
rape 389
rapid eye movement (REM) sleep 619–20
rapid-eye-movement sleep behavior disorder (RBD) 527, 531, 624
Rattus norvegicus model of aging 67–9
reactive oxygen species (ROS) 63
reafference 325
real time location systems (RTLS) 211
real-world observations 204–17
cf in clinic and laboratory 205–6
classification and tracking human movement and energy expenditure 206–8
crowd-source reports of behaviors 217
energy expenditure 212
experience sampling method (esm) 208–9
incorporating digital data from the internet and social network tools 216–17
inferences on causality 210
locating the subject 211–12
perspectives for following a person in context 211
social sensors 213–14
telehealth 214
tool-driven revolution 209–10
tracking physiology 212–13
video images in public and private spaces 214
reasonable factor other than age (RFOA) defense 753, 755
reasoning capacity 692
receptive aphasia 116
Reckart, Timothy 91f
Recovery Memory Test 136
reflex urinary incontinence 392
reflexes 362, 549
examination of 119
rooting 110
Reid v. Google, Inc. 754
relaxation response 549
relaxation techniques 640t
REM sleep behavior disorder 624
Rembrandt van Rijn 95
Self-Portrait (c. 1629; age 22) 86f
Self-Portrait as Zeuxis Laughing (c. 1663; age 56) 86f
self-portraits 85, 87
reminiscence therapy 85
representational knowledge operational processes 255
residential care 677–81
assisted living 677–9
nursing home care 678–81
hospice 679–80
special care units 679
resources for 681–2
rest tremor 526
resting state fMRI 155
resting state network (RSN) 155
resting-state functional connectivity (RSFC) 155
restless leg syndrome 623
Resveratrol 50
retinal pigment epithelial layer (RPE) 298
retrocollis 555
Ret割星 (film) 79, 96f
retronsinusular cortex 321
reversible cerebral vasoconstriction syndrome 492, 573
Rey Auditory Verbal Learning Test (RAVLT) 135
Rey Complex Figure test 138
Rey Osterrieth Complex Figure test (CFT) 136
rheumatoid arthritis 512, 573
Riddoch phenomenon 306t
rigidity 110
Ringgold, Faith 87
Rinne test 115
rivastigmine (Exelon) 462t, 463, 464, 712
Roadmap Initiatives 231
Robot and Frank (film) 91
rodent model of aging 67–70
Rodin: Old Woman, The 87
rod-mediated dark adaptation 302, 303, 303f
Rohypnol 390
romance 389
reminiscence therapy 85
Index

rooting reflex 110
rotational torticollis 537
rotenone 52
Rotterdam Elderly Pain Observation Scale (REPOS) 637t
Saar, Betye 87
Destiny of Latitude & Longitude, The 87
Sabat, Steven: Experience of Alzheimer’s Disease, The: Life Through A Tangled Veil 84
saccades 321
Sacks, Oliver: “Joy of Old Age (No Kidding), The” 84
sadness 419
sadomasochism 389
SAGE Story 93
San Francisco State University: Legacy Film Festival on Aging 91
Sarton, May 82
Savages, The (film) 92
Scaffolding Theory of Cognitive aging (STAC) 155
Scarpa’s ganglion neuronal loss 327
schizophrenia 106, 545–7
balance and gait impairment in 317
Schloendorff v. Society of New York Hospital 726
Schultz, Susan M.: Dementia Blog 84
Schur, Laurie 92
scleroderma 512
scotopic sensitivity 302
scotopic vision 302–3
Scott, Ridley 91
sculpture and other multimedia 87
secondary injury 602
secondary seizures 555
β-secretase (BACE) 466
γ-secretase (presenilin) 466
sedentary behavior 652t
selective attention 338
attentional capture 348, 349–51
enhancement and inhibition 346–51
overt orienting of 343
Stroop effects 346–8, 347f
task-switching 351
selective optimization with compensation model (SOC) 425
selective optimization with compensation—Emotion regulation model (SOCER) 425–6
selective serotonin reuptake inhibitors (SSRIs) 698
selegiline 464
self-awareness and autonomy 691
self-care competence 674
self-concept 80
self-conscious emotions 421
self-determination 690–1
self-neglect 694
self-regulation 255, 256
semantic dementia (SD) 265
senescence-associated secretory phenotype (SASP) 46
senescence-associated β-galactosidase (SABG) 46
sensorineural hearing loss (SNHL) 331
sensory examination 110
sensory presbycusis 330
sensory tricks 533
sentence processing 282–3
comprehension 282–3
production 283
sepsis-associated encephalopathy 563–4
serotonin syndrome 579
sex differences in emotions 422
sexual dysfunction 389–409
cerebral substrates 389–91
CNS Substrates of 389–91
sexual relations 730f, 736
SF-12 239
SF-36 generic HRQOL family 238–9, 240
SF-6D 240
shame 421
shingles 114
Shinohara, Ushio and Noriko 87, 92
short stories 83
short-term memory 272
Shy Drager Syndrome 530
shyness 421
Siemens’ Syngo 177
silent infarction 510
silent information regulator 2 (Sir2) proteins 48, 50
silent strokes 483
Simmel, Joan 87
single photon emission computed tomography (SPECT) 124
in AD 453
sirolimus 49
situation models 284
Sjögren’s syndrome 512, 573
sleep and sleep disorders 619–24
changes in sleep architecture 619–20
causes of sleep disturbances 620–1
medical illness and medications and 620t
neurodegenerative disorders 621–3
dementia 621–2
parkinson’s disease 622–4
psychiatric illnesses 621
sleep attacks 527
small vessel atherosclerosis 491
small vessel disease 491, 510
smart buildings 213
smart homes 213
susceptibility-weighted imaging (SWI) 149, 494
sustained-attention-to-response task (SART) 340
Swift, Jonathan 82
Gulliver’s Travels 82, 82(box)
sympathomimetic drug abuse 492
symptomatic seizures 555
Syntermed’s NeuroQ 177
syphilis 512, 573
systems integration software 663
T2-weighted or FLAIR scans 150
tachypnea 527
tacrine (Cognex) 462, 462t
Takayasu’s arteritis 484
tardive dyskinesia 557–8
Targeting Aging with Metformin (TAME) 765
task-enabling technologies 217–19
task-negative DMN 155
task-related fMRI 154
Task-switching 351
taste 112
tau imaging 183
tau-protein in 63, 124, 455, 456, 460–1
tauopathies 66
Taylor Complex Figure (TCF) Test 136, 138
Taylor, Richard: Alzheimer’s from the Inside Out 84
Team Science for the aging mind and brain 766–7
telangiectasias 494
telehealth 214
telemedicine 214
temporal intermittent rhythmic delta activity (TIRDA) 192
Tensor Based Morphometry (TBM) 601
terminal insomnia 542
Test of Memory Malingering 139
Testamentary capacity (making a will) 725, 730f
Thatcher, Margaret 92
Theory of Mind (ToM) 95, 261
Thor (film) 91
thought, behavior, and personality change 106–7
thunderclap headache of subarachnoid hemorrhage 573
thyroid storm 558
tilt-translation ambiguity 324
tip-of-the-tongue (TOT) states 282
Titian 85
TOAST (Trial of ORG 10172 in acute stroke treatment) criteria 488
Token Test 137
Toledano, Philip: Days with My Father 87
Tolstoy, Leo 92
topographagnosia 306t
TOR 48
Tower of Hanoi test 138
Tower of London test 138
tower tests 138
Trail Making Test 139
tramiprosate 468
transcranial direct current stimulation (tDCS) 698
transcranial Doppler sonography (TCD) 123
transcranial magnetic stimulation (TMS) 698
transient ischemic attack (TIA) 485–7
Translational Science 765
translational VOR (TVOR) 324
translation-tilt ambiguity 326
trauma 103
traumatic brain injury 390, 591–613
aging brain and 598–600 blast-associated TBI and risk for CTE 600
link to progressive brain disease 598–9
risk for neurodegenerative disease 599–600
biomarkers 596
causes of moderate or severe TBI 597
chronic case study 605–9
clinical manifestations 607 coexisting proteinopathies 608 diagnosis 610
historical background 605–7
microscopic features 609f
neuropathology 607–8
proposed pathologic stages 608
treatment 612
clinical assessment 594 definitions 593–5
delayed neurodegeneration 600–5
aβ versus tau 604–5
macromolecular changes after 603–4
mechanistic considerations 600
pathophysiology of acute TBI 600–2
post-traumatic amyloidosis 603–4
post-traumatic neuroinflammation 602–3
post-traumatic tauopathy 604
hyperphosphorylation 604
tau propagation 605
tauopathy treatment considerations 605
epidemiology 596–7
limitations on accuracy of reporting 596–7
medical coding 595
mild 591–2, 597
public health impact 593
young athletes 592–3
neurodegenerative proteinopathies 610
research coding 595
research in vulnerable populations 612
severity 594
treatment 598
youth sports and the developing brain 612–13
tremor 523, 533–4, 556
cerebellar 534
dystonic 534
essential 533, 534f
physiologic 533
psychogenic 534
treatment 533
treponemal infection 390
triaxial accelerometer system 208
trigeminal neuralgia 114
Trollope, Anthony 82
Warden, The 82
Trousseau’s test 557
true epileptic seizures 208
Truman Show, The 219
Twitter 216
unconscious urinary incontinence 392
Urinary (film) 92, 93f
Undec Influence 735–6
Uniform Guardianship and Protective Proceedings Act (UGPPA) 729
Up (film) 91
uremic encephalopathy 559–60
urge urinary incontinence 391, 394–6
urinary incontinence
classification of urinary incontinence 391–2
evaluation of 392, 393f
functional 392
incidence, prevalence, and cost 391
conservative management 394
behavioral techniques 394
pharmacologic treatment 394–5
urge incontinence 394–5
surgical treatment 395–6
urge incontinence 395–6
stress incontinence 396
management 394–6
US Food and Drug Administration (FDA) 232–3, 233f, 234t
Guidance for Industry: Patient-Reported Outcome Measures 232
US government spending on Alzheimer’s research 707f
on top 10 conditions in 2013 706t
useful field of view (UFOV) 304, 340, 343, 345–6
Utermohlen, William 87
vaginal cones 394
valproic-induced hyperammonemic encephalopathy 581
values, changing, at the end of life 695(box)
vascular (lower body) parkinsonism 527
vascular cognitive impairment 510, 515t
vascular dementia 120t, 510, 514
sleep in 625
vascular mild cognitive impairment (VaMCI) 514
vascular parkinsonism 532
vasoactive intestinal peptide in erectile dysfunction 401
venereal disease 390
verbal working memory 285
Vertigo Symptom Scale 328
vestibular cortex 321
vestibular migraine 328
vestibular nuclei (VN) 321, 322, 322f, 326f
types of 324
vestibular afferents reach 323f
vestibular organs, hair cells 321
vestibular pacemaker 328
vestibular prostheses 328
vestibular spinal reflexes (VSR) 321, 325
vestibular stimulation, galvanic and caloric 326
vestibular system 318–28
anatomy of 319–21, 320f
changes with aging 327–8
function of 324–7
physiology of 321–4
vestibular-only (VO) neurons 324
vestibule-ocular reflex (VOR) 115, 322, 323f
vestibulo-collic reflex (VCR) 324
VFQ questionnaire 308
viral encephalitis 562, 563
viral meningitis 562–3
vision 112
and aging 296–308
changes, effect on activities of daily life 307–8
vision problems in older adults 300–5
rod-mediated dark adaptation 302, 303, 303f
scotopic vision 302–3
spatial contrast sensitivity 301, 302f
visual acuity 138, 300–1, 300f
visual field 303–4
vision problems in older adults (cont’d)
visual processing 304–5
visual acuity 138, 300–1, 300f
visual agnosias 138
visual analogue scale (VAS) methods 236
visual art 85–90
aging mind in 87
discussion 89
self-expression through 89
therapeutic uses of, for older adults 89–90
visual distortions 307t
visual field 303–4
visual forms of reminiscence 89
visual hallucinations 106, 305, 307t
in dementia with Lewy bodies 547
in PD 546–7
visual impairment and aging-related eye conditions, epidemiology of 298–300
from cerebral disorders 305–7, 306–7t
visual processing 304–5, 304f
vital signs and pain assessment 108–9
vitamin A deficiency 303
vitamin E 462t, 464–5
Vogt-Koyanagi-Harada diseases 562
volunteering 25, 28
Vonnegut, Kurt: Galápagos 691
vox-populi (“wisdom of crowds”) 217
VZV meningitis 562, 563
wake after sleep onset (WASO) 619
Walken, Christopher 92
Wallenberg syndrome 484
Warhol, Andy 87
Weber test 115
Wechsler Adult Intelligence Scale (WAIS) 135
WAIS IV 135
Wechsler Memory scale 136–7
Faces subtest 136
Logical Memory subtest 136
Wegener’s granulomatosis 512
weight loss 108
Werner syndrome 40, 42
Wernicke’s aphasia 116, 484
Wernicke’s area 279
Wernicke’s encephalopathy 560–1, 561f
West Nile virus (WNV) 563
Wexler, Alice: Mapping Fate: A Memoir of Family, Risk, and Genetic Research 84
Whipple’s disease 390
white matter disorders 509–16
causes 511t
clinical presentation 514–16
etiopathogenesis 511–12
neuroimaging 512–13
prevention 516
treatment 516
White, Betty 91
Whitehouse, Peter 95
WHO generic QOL family instruments 227
WHOQOL family of QOL instruments 227
WHOQOL-100 226, 236, 237
WHOQOL-BREF 236, 237, 243
WHOQOL-OLD 242, 243
WHOQOL-OLD113 243
Wild Strawberries (film) 91
Williams, Ted 764
Wisconsin Card Sorting Task (WCST) 138, 656
word learning 289
Word Memory Test 139
Wordsworth, Dorothy 82
work system model 665f
working memory 258–60, 272
World of Warcraft (WoW) 217
writer’s cramp 535
writing 82–5
X-Men (film) 91
Yohimbine in erectile dysfunction 400
You’re Looking at Me Like I Live Here And I Don’t (documentary) 92, 94f
Young@Heart (documentary) 92
zoophilia 389